Real-world Evidence

Real-world Evidence (RWE) refers to data and information derived from routine clinical practice, including electronic health records (EHR), medical device registries, patient-reported outcomes (PROs), and insurance claims data. Unlike traditional randomized controlled trials (RCTs), RWE captures diverse patient populations and long-term outcomes in unselected settings. Regulatory bodies like the US FDA and European EMA have increasingly accepted RWE for regulatory decision-making, including drug approvals and medical device post-market surveillance. In the context of ISO 14121 and ISO 14971, RWE provides the necessary input for continuous risk-adjusted benefit-risk assessment, ensuring that the product's safety profile remains valid throughout its lifecycle. This is critical for maintaining compliance as regulatory expectations evolve globally.

The application of RWE in enterprise risk management typically follows a three-stage framework: Data--centricity, Analytical Rigor, and Strategic Decision-making. First, companies must establish robust data-gathering pipelines that comply with international standards like GDPR and the Taiwan Personal Data Protection Act (PDPA). Second, advanced statistical methods, such as propensity score matching and propensity-adjusted analysis, are used to control for confounding factors inherent in non-randomized data. Third, the insights are integrated into the Risk-Adjusted Benefit-Risk Assessment (RABRA)-a process where RWE is compared against pre-market clinical data to trigger necessary regulatory actions. For example, a medical device manufacturer using RWE to track device-related adverse events in real-time can proactively issue safety alerts, reducing legal liability by up to 40% and improving patient safety outcomes by 15% within the first year of implementation.

Taiwan enterprises face three primary challenges: Data Silos, Regulatory Ambiguity, and Talent Scarcity. Data Silos occur because hospital systems, the National Health Insurance Administration (NHIA), and private insurers use incompatible data formats; the solution is to adopt HL7 FHIR standards for interoperable data exchange. Regulatory Ambiguity arises as the TFDA is still refining RWE acceptance criteria; companies should be closely closely monitoring FDA and EMA updates and proactively engaging in pre-submission consultations with TFDA. Talent Scarcity is the most critical bottleneck, as RWE analysis requires a rare combination of clinical, statistical, and regulatory expertise. The optimal approach is to partner with specialized consultants like Winners Consulting Services Co., Ltd. to bridge the knowledge gap while upskilling internal quality and regulatory affairs teams over a 12-month roadmap.

Winners Consulting Services Co., Ltd. specializes in Real-world Evidence for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact